Adaptive Biotechnologies Corp vs iShares Semiconductor ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while iShares Semiconductor ETF trades at $546.66. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares Semiconductor ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | SOXX | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Sector/Thematic |
52-Week High | $25.45 | $655.01 |
52-Week Low | $12.30 | $241.68 |
Enterprise Value | $4.10B | — |
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
SOXX trades at $552.56, up 4.24% with a bullish technical signal from moving averages. The semiconductor ETF faces mixed sentiment as recent news highlights sector rotation away from chips toward software, though major cloud companies' strong earnings support AI infrastructure demand. Technical indicators show neutral oscillators with key resistance at $548.
Outlook remains cautiously optimistic given AI-driven semiconductor demand, but risks include tariff impacts, concentration in 30 stocks, and potential overvaluation after 2026 gains. Institutional buying (Bank of America increased holdings 20.9% in Q1 2026) signals confidence, yet investor caution is warranted amid sector volatility.
Trailing returns across standard periods
Latest headlines on both assets
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →